FeesSafety
Pluang+

3 dividend stocks—Johnson & Johnson, Realty Income, Chevron—offer reliable payouts backed by strong cash flow and solid balance sheets.

Market News
08 Nov 2026, 15:32 WIB
24/7 Wall Street
View Source
Bullish
3 dividend stocks—Johnson & Johnson, Realty Income, Chevron—offer reliable payouts backed by strong cash flow and solid balance sheets.

Three dividend stocks from healthcare, real estate, and energy sectors—Johnson & Johnson, Realty Income, and Chevron—stand out for their reliable dividends supported by strong cash flow and manageable debt. Johnson & Johnson boasts 64 years of consecutive dividend increases with a payout covered by nearly half its earnings, despite ongoing talc litigation risks. Realty Income offers a high 5.2% yield with 116 straight quarterly dividend raises, supported by long-term leases and a strong balance sheet, though rising interest costs pose a risk. Chevron combines 39 years of dividend growth with robust free cash flow and a conservative balance sheet, but fluctuating oil prices remain a key risk. Together, these stocks provide diversified income streams for retirement portfolios.

Johnson & Johnson trades at USD 276.22 with a 1.94% dividend yield on Pluang as of Nov 08, 2026 20:41 WIB. Realty Income offers a 5.52% yield, priced at USD 59.04, despite a 0.77% decline in one day. These dividend stocks show varied investor interest, with JNJ nearly balanced in buy and sell orders, while Realty Income has 100% buy orders on Pluang.

More News (JNJ)

New data shows nipocalimab improves mouth dryness in Sjögren's disease, with Phase 3 trials underway.

New data shows nipocalimab improves mouth dryness in Sjögren's disease, with Phase 3 trials underway.

Johnson & Johnson announced new patient data from the Phase 2 DAHLIAS study showing nipocalimab significantly improves mouth dryness, the most impactful symptom for Sjögren's disease patients. The drug also increased saliva production by 50% in more ...

Company Fundamentals
Bullish
1 day ago
ICOTYDE shows strong Phase 3 results for psoriatic arthritis with 58% ACR20 response at 16 weeks

ICOTYDE shows strong Phase 3 results for psoriatic arthritis with 58% ACR20 response at 16 weeks

Johnson & Johnson announced positive Phase 3 trial results for ICOTYDE (icotrokinra), an oral peptide targeting IL-23R, in treating biologic-naïve adults with active psoriatic arthritis. At 16 weeks, 58% of patients achieved ACR20 response versus 41%...

Company Fundamentals
Bullish
1 day ago
Dividend stocks may offer higher income than the 1.76% average 1-year CD rate in 2026.

Dividend stocks may offer higher income than the 1.76% average 1-year CD rate in 2026.

As of late 2026, the average 1-year certificate of deposit (CD) rate stands at 1.76%, below the Federal Reserve's target range. Some investors are considering blue-chip dividend stocks like Microsoft, Johnson & Johnson, and Coca-Cola, which offer pot...

Bullish
2 days ago
FDA approves RYBREVANT FASPRO for advanced head and neck cancer after chemo and immunotherapy failure

FDA approves RYBREVANT FASPRO for advanced head and neck cancer after chemo and immunotherapy failure

The FDA granted accelerated approval to Johnson & Johnson's RYBREVANT FASPRO, a dual-targeted therapy for adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) who have progressed after platinum-based chemotherapy and anti...

Market News
Bullish
2 days ago
Five high-yield dividend stocks offer stable income amid market downturn risks.

Five high-yield dividend stocks offer stable income amid market downturn risks.

Five dividend-paying stocks in sectors like pharmaceuticals, software, food, and utilities are highlighted for their strong dividend coverage and resilience during economic slowdowns. Johnson & Johnson, IBM, Pfizer, General Mills, and Dominion Energy...

Neutral
2 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App